

ITF Rare Diseases Norway

Accessibility remediation findings

Date: 28 April 2026

Scope: Norwegian HCP website pages reviewed during the audit

Summary of findings

Prioritized technical findings prepared for remediation planning

ID	Area	Finding	Severity
NO-001	Home page CTA cards	Heading structure and link markup	Medium
NO-002	DMD pages	Slider arrow links missing accessible names	Medium
NO-003	DMD pages	Low contrast on “Se video” control	Medium
NO-004	Global CTA cards	Keyboard focus indicator is too subtle	Medium
NO-005	Duvyzat pages	Product image has empty alt text	Medium / Needs decision
NO-006	Global clinical images	Clinical information in images needs text alternatives	High
NO-007	Video cards	Video/card link has no discernible accessible name	Medium
NO-008	Scientific updates	Heading hierarchy should be reviewed	Medium
NO-009	Mobile menu	Off-canvas controls may lack accessible names	Medium / Needs verification

HOME PAGE | CTA cards – heading structure and link markup

Area: Home page CTA cards



Severity: Medium

ISSUE

The CTA cards use an illogical heading structure. The visible CTA label “Finn ut mer” is marked up as a heading, while the actual card title is placed at a lower heading level.

WHY THIS MATTERS


Screen reader users often navigate by headings. Incorrect heading levels make the page structure harder to understand and navigate.

RECOMMENDED FIX

Use semantic markup that reflects the visual hierarchy. Use regular text/span for “Finn ut mer”, use a logical heading level for the actual card title, ensure the full card link has a clear accessible name, and hide decorative SVG arrows from assistive technologies.

DMD PAGES | Slider arrows – missing accessible names

Area: DMD pages and video/slider modules



Severity: Medium

ISSUE

The slider navigation arrows are implemented as icon-only links. The link contains only an SVG icon and no visible text or accessible name.

WHY THIS MATTERS

Screen reader users may only hear “link” with no description. Users navigating by links or buttons cannot understand whether the control moves to the next or previous slide.


RECOMMENDED FIX

Add a clear accessible name to each slider control and hide decorative SVG icons from assistive technologies.

```
<a class="elementor-button" href="#next-slide" aria-label="Next slide">
  <svg aria-hidden="true" focusable="false">...</svg>
</a>
```

DMD PAGES | “Se video” control – insufficient contrast

Area: DMD video/slider module



Severity: Medium

ISSUE

The foreground and background colors for the “Se video” control do not provide sufficient contrast. The issue is visible on the video hero/slider area.

WHY THIS MATTERS

Low contrast text can be difficult or impossible to read for users with low vision, color vision deficiencies, or users viewing the page in poor lighting conditions.

RECOMMENDED FIX

Increase the contrast between the “Se video” text/control and its background. Use a darker or lighter color combination that meets WCAG AA contrast requirements. For normal text, target at least 4.5:1. For large text or non-text UI components, target at least 3:1.

```
.video-button {
  color: #ffffff;
  border-color: #ffffff;
  background-color: rgba(26, 0, 81, 0.85);
}
```

GLOBAL | Focus indicator – low visibility on CTA cards

Area: CTA cards and link cards across the site



ISSUE

The CTA cards do have a visible keyboard focus indicator, but the blue outline is subtle and may be hard to notice.

Severity: Medium

WHY THIS MATTERS

Keyboard users rely on the focus indicator to understand where they are on the page. If it is too subtle, users may lose track of their position.

RECOMMENDED FIX

Make the focus indicator more visually prominent across all CTA/link card components. Use a thicker outline, strong contrast color and outline offset. Recommended color #ED6F2F.



Severity: Medium



DUVYZAT PAGES | Product image – missing descriptive alt text

Area: Product information section

Hva er Duvyzat®?

- Duvyzat® er en oral behandling som hjelper ambulante pasienter med Duchennes muskeldystrofi (DMD) med å bevare muskelfunksjonen og forsinke sykdomsprogresjonen.¹⁻⁶
- Duvyzat® er en flytende suspensjon i en flaske som skal administreres to ganger daglig i en vektavhengig dose ved bruk av en gradert sprøyte.⁷

Hvem er Duvyzat® indisert for?

- Duvyzat® er indisert for behandling av DMD hos ambulante pasienter, 6 år og eldre, og med samtidig kortikosteroidbehandling.⁷
- Duvyzat® er en DMD-mutasjonsuavhengig behandling.^{2,7}



ISSUE

The product image has empty alt text. Empty alt text tells screen readers to ignore the image.

WHY THIS MATTERS

This is correct for decorative images, but this image may provide useful product context because it shows the medication form, packaging and dosing syringe.

RECOMMENDED FIX

Confirm whether the image is decorative or informative. If informative, add short descriptive alt text. If all relevant information is already in nearby text, empty alt text may be acceptable.

alt="Duvyzat oral suspension with bottle, packaging and dosing syringe"

GLOBAL | Clinical information in images – text alternatives required

Area: Clinical tables, dosing images and monitoring guidance

Doseringsjusteringer ved bivirkninger:

Faktisk kroppsvekt ^(a)	Første doseringsjustering ^(b)		Andre doseringsjustering ^(c)	
	Dose	Volum av oral suspensjon	Dose	Volum av oral suspensjon
15 kg til under 20 kg	17,7 mg to ganger per dag	2 ml to ganger per dag	13,3 mg to ganger per dag	1,5 ml to ganger per dag
20 kg til under 40 kg	22,2 mg to ganger per dag	2,5 ml to ganger per dag	17,7 mg to ganger per dag	2 ml to ganger per dag
40 kg til under 60 kg	31 mg to ganger per dag	3,5 ml to ganger per dag	26,6 mg to ganger per dag	3 ml to ganger per dag
60 kg eller mer	39,9 mg to ganger per dag	4,5 ml to ganger per dag	35,4 mg to ganger per dag	4 ml to ganger per dag

- a) Basert på faktisk kroppsvekt.
b) Dersom bivirkningen(e) vedvarer etter den første dosejusteringen, fortsett til den andre dosejusteringen.
c) Dersom bivirkningen(e) vedvarer etter den andre dosejusteringen, skal Duvyzat[®] seponeres.

Seponering:

- ◆ Dersom bivirkningen(e) vedvarer etter den andre dosejusteringen, skal Duvyzat[®] seponeres.
- ◆ Forlengelse av QTc-intervallet: Avslutt Duvyzat[®] dersom QTc-intervallet er >500 ms eller endringen fra baseline er >60 ms.

ISSUE

Images that contain clinical information should be reviewed to confirm whether they have appropriate alt text or an equivalent text alternative.

WHY THIS MATTERS

Clinical and dosing information is critical content. Users who cannot see the image need access to the same information in text or structured HTML. A short alt text is not sufficient for complex tables.

RECOMMENDED FIX

Review all clinical images and classify them as decorative or informative. For informative clinical images, provide the same information as real HTML text/table. Use semantic table markup where possible.

```

<table>...</table>
```

Severity: High

VIDEO CARDS | Link has no discernible accessible name

Area: Webinar/video card components



Severity: Medium

ISSUE

A clickable video/card element appears to be exposed as a link without a clear accessible name. If the link name is empty, icon-only, or not derived from the visible card title, screen reader users cannot understand what the link opens.

WHY THIS MATTERS

Screen reader users and users navigating by links need each link to have a unique and meaningful name. A generic or empty link makes the video content difficult to discover and activate.


RECOMMENDED FIX

Ensure the clickable card has a clear accessible name based on the visible video title. If the whole card is a link, the accessible name should include the title, for example "From clinical trials to clinical practice". Hide decorative arrow icons from assistive technologies.

```
<a href="..." aria-label="Watch video: From clinical trials to clinical practice">
  ...
  <svg aria-hidden="true" focusable="false">...</svg>
</a>
```

SCIENTIFIC UPDATES | Heading hierarchy should be reviewed

Area: Scientific updates page



Severity: Medium

ISSUE

The page title should be the only h1. Main sections that sit directly under the page title should normally use h2. Card/video titles can use h3 if they are grouped under a clear h2 section, but h3/h4 should not be used just for visual styling or skipped without a parent heading.

WHY THIS MATTERS

Screen reader users often navigate by headings. If heading levels are skipped or used for styling rather than structure, the page outline becomes harder to understand.

RECOMMENDED FIX

Review the page outline and update heading levels to match the content hierarchy. Keep the visual styling separate from the semantic heading level.

```
<h1>Vitenskapelige oppdateringer</h1>
<h2>Velg innhold</h2>
<h3>From clinical trials to clinical practice</h3>
```

MOBILE MENU | Off-canvas controls may lack accessible names

Affected area: Elementor mobile/off-canvas menu controls



Severity: Medium / Needs verification

ISSUE

If the off-canvas menu open/close controls are focusable and do not have visible text or an aria-label, their purpose may not be exposed to assistive technologies.

WHY THIS MATTERS

Screen reader and keyboard users need clear names for menu controls so they can open and close navigation reliably.

RECOMMENDED FIX

Verify the mobile menu controls. Add accessible names such as “Open menu” and “Close menu” if the controls are exposed as links/buttons.

```
<button aria-label="Open menu">...</button>  
<button aria-label="Close menu">...</button>
```